Loading publications…
The last 5 uploaded publications
Two decades of advances in clinical oncology — lessons learned and future directions
Susana Banerjee, Christopher M. Booth, Éduardo Bruera, Markus W. Büchler, Alexander Drilon, Terry J. Fry, Irene M. Ghobrial, Luca Gianni, Rakesh K. Jain, Guido Kroemer, Josep M. Llovet, Georgina V. Long, Klaus Pantel, Kathy Pritchard‐Jones, Howard I. Scher, Josep Tabernero, Ralph R. Weichselbaum, Michael Weller, Yi‐Long Wu (2024). Two decades of advances in clinical oncology — lessons learned and future directions. Nature Reviews Clinical Oncology, 21(11), pp. 771-780, DOI: 10.1038/s41571-024-00945-4.
Article145 days agoPhase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. , DOI: https://doi.org/10.1158/2767-9764.crc-24-0601.
Article62 days agoDurability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. , 183, DOI: https://doi.org/10.1016/j.ejca.2023.01.016.
Article62 days agoFigure 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Figure 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. , DOI: https://doi.org/10.1158/2767-9764.28471007.
Preprint62 days agoTable S4 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Table S4 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. , DOI: https://doi.org/10.1158/2767-9764.28470971.
Preprint62 days ago